The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Daniel G. Wolle - JPMorgan Chase & Co, Research Division - Analyst
: This is Daniel Wolle for Jessica Fye. This question is for Dr. Diab, Dr. Curti. In the real world, do you think clinicians will add the BEMPEG to single-agent
(inaudible), assuming that BEMPEG is approved based on the current Phase II studies?
Question: George Farmer - BMO Capital Markets Equity Research - Analyst
: I was wondering one of the panelists, maybe, Adi, could you comment on the difference in, if any, in the patients who just don't respond at all to
BEMPEG nivo that seems similar to what was seen in CheckMate 067, where you do get this maybe about 1/3 of the patients just don't benefit at
all.
Are you seeing a reduction in that number in PIVOT? Where is this effect coming from? Is it coming from that? Or is it maybe more apparent in the
tail?
And then JZ, I wasn't going to go there, but maybe you could just comment on whether you're seeing any differences in PFS or OS based on the
batch of BEMPEG that the patients received?
Question: Arlinda Anna Lee - Canaccord Genuity Corp., Research Division - Analyst
: I have a couple. Could you first maybe provide additional color on the 262 discontinuation? And then maybe on the depth of response for the
frontline melanoma patients are there predictors of response and relapse in the biomarkers? And I'm kind of curious about how long you guys or
the KOLs would continue to dose these patients on [CRs] how do you think about the cadence of the response, deepening of responses, potential
late immune AEs in the course of treatment?
Question: Arlinda Anna Lee - Canaccord Genuity Corp., Research Division - Analyst
: Yes. Sorry. Let me just put it another way, could I circle back with you on that?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
NOVEMBER 11, 2020 / 9:15PM, NKTR.OQ - Nektar Therapeutics Analysts Call with Expert Oncologist Panel
During 2020 Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting
|
